Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Online Ordering Portal Signup

Are you a healthcare professional? Sign up for an online ordering account on this form for healthcare professionals. If you are a ROL, enter your information on this form for ROLs.